DelveInsight's "Leber's Hereditary Optic Neuropathy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Leber's Hereditary Optic Neuropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Leber's Hereditary Optic Neuropathy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Leber's Hereditary Optic Neuropathy: An Overview
Leber's Hereditary Optic Neuropathy (LHON) is a distinct type of “inherited optic atrophies” or “hereditary optic neuropathies.” It refers to an optic nerve dysfunction due to point mutations in the mitochondrial DNA and is transmitted in a non-mendelian pattern.
The primary cell type lost in LHON is the retinal ganglion cell, which is highly susceptible to disrupted ATP production and oxidative stress. Inheritance of LHON follows mitochondrial genetics, and it has a highly variable clinical phenotype, as other genetic and environmental factors also play a role.
LHON is maternally inherited, and both male and female offspring can inherit the mutation, yet 50% of males and only 10% of females experience vision loss. Also, it has been hypothesized that a recessive X-linked susceptibility gene works in concert with the mitochondrial mutation, which could explain the male predominance among carriers who lose vision.
Leber's Hereditary Optic Neuropathy Market Key Facts
-
The prevalence of Leber's Hereditary Optic Neuropathy is thought to be around 1/50,000 worldwide.
-
Leber's Hereditary Optic Neuropathy affects approximately 10,000 people in the United States and can lead to legal blindness.
-
The prevalence of Leber's Hereditary Optic Neuropathy has been well established in Northern European populations, with figures ranging from 1/30,000 to 1/50,000.
-
Leber's Hereditary Optic Neuropathy is estimated to be the most frequent mitochondrial disease, with a prevalence ranging from 1/27,000 in North East England to 1/45,000 in a meta-analysis of reports in the European population.
-
The largest study of Leber's Hereditary Optic Neuropathy demographics reported a 3:1 male-to-female ratio, with women carrying a Leber's Hereditary Optic Neuropathy mutation at a higher risk of losing vision than is generally expected.
Leber's Hereditary Optic Neuropathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Leber's Hereditary Optic Neuropathy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Leber's Hereditary Optic Neuropathy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Leber's Hereditary Optic Neuropathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Leber's Hereditary Optic Neuropathy (LHON) Epidemiology Segmented as -
-
Total Prevalent cases of LHON (2019–2032)
-
Gender-specific cases of LHON (2019–2032)
-
Diagnosed and Treatable cases of LHON (2019–2032)
Leber's Hereditary Optic Neuropathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Leber's Hereditary Optic Neuropathy market or expected to be launched during the study period. The analysis covers the Leber's Hereditary Optic Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Leber's Hereditary Optic Neuropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Leber's Hereditary Optic Neuropathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Leber's Hereditary Optic Neuropathy Therapeutics Analysis
The mainstay of clinical treatment for LHON remains supportive rather than curative. The management of LHON patients includes low vision aids, occupational rehabilitation, and registration with local social services. Those with mitochondrial mutations should be advised to refrain from smoking and binge alcohol drinking. Furthermore, screening for extraocular manifestations should be carried out in the form of an electrocardiogram and complete neurological evaluation.
Several major pharma and biotech giants are developing therapies to treat Leber Hereditary Optic Neuropathy and improve the treatment scenario. Currently, GenSight Biologics is leading the therapeutics market with its Leber Hereditary Optic Neuropathy drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Leber's Hereditary Optic Neuropathy (LHON) Therapeutics Market Include:
-
Fortify Therapeutics
-
GenSight Biologics
-
Mitotech
-
Neurophth Therapeutics
-
Neuroptika
-
Stealth BioTherapeutics
And many others
Leber's Hereditary Optic Neuropathy (LHON) Drugs Covered in the Report Include:
-
GS010: GenSight Biologics
-
Elamipretide: Stealth BioTherapeutics Inc.
And many more
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Leber's Hereditary Optic Neuropathy Competitive Intelligence Analysis
4. Leber's Hereditary Optic Neuropathy Market Overview at a Glance
5. Leber's Hereditary Optic Neuropathy Disease Background and Overview
6. Leber's Hereditary Optic Neuropathy Patient Journey
7. Leber's Hereditary Optic Neuropathy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Leber's Hereditary Optic Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Leber's Hereditary Optic Neuropathy Unmet Needs
10. Key Endpoints of Leber's Hereditary Optic Neuropathy Treatment
11. Leber's Hereditary Optic Neuropathy Marketed Products
12. Leber's Hereditary Optic Neuropathy Emerging Drugs and Latest Therapeutic Advances
13. Leber's Hereditary Optic Neuropathy Seven Major Market Analysis
14. Attribute Analysis
15. Leber's Hereditary Optic Neuropathy Market Outlook (In US, EU5, and Japan)
16. Leber's Hereditary Optic Neuropathy Access and Reimbursement Overview
17. KOL Views on the Leber's Hereditary Optic Neuropathy Market
18. Leber's Hereditary Optic Neuropathy Market Drivers
19. Leber's Hereditary Optic Neuropathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
